TuisEVGN • NASDAQ
add
Evogene Ltd
Vorige sluiting
$1,60
Dagwisseling
$1,52 - $1,67
Jaarwisseling
$1,44 - $10,40
Markkapitalisasie
8,19 m USD
Gemiddelde volume
556,08 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 1,80 m | -52,32% |
Bedryfskoste | 8,17 m | 9,83% |
Netto inkomste | -7,63 m | -91,52% |
Netto winsgrens | -424,83 | -301,69% |
Wins per aandeel | -1,31 | -63,75% |
EBITDA | -6,83 m | -93,87% |
Effektiewe belastingkoers | -0,01% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 19,95 m | -46,40% |
Totale bates | 40,11 m | -30,53% |
Totale aanspreeklikheid | 27,88 m | 27,39% |
Totale ekwiteit | 12,24 m | — |
Uitstaande aandele | 6,79 m | — |
Prys om te bespreek | -2,50 | — |
Opbrengs op bates | -45,97% | — |
Opbrengs op kapitaal | -110,69% | — |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -7,63 m | -91,52% |
Kontant van bedrywe | -4,93 m | -14,15% |
Kontant van beleggings | 2,02 m | -44,68% |
Kontant van finansiering | 4,73 m | -39,30% |
Netto kontantverandering | 1,83 m | -74,18% |
Beskikbare kontantvloei | 757,88 k | 124,92% |
Meer oor
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
HUB
Gestig
2002
Webwerf
Werknemers
142